



PB 101 of 2025

National Health (Minimum Stockholding) Amendment Determination (No. 8) 2025

I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.

Dated 25 August 2025

Rebecca Richardson
Assistant Secretary
PBS Listing, Pricing and Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 September 2025	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 October 2025	9
<i>National Health (Minimum Stockholding) Determination 2023</i>	9

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 8) 2025*.
- (2) This instrument may also be cited as PB 101 of 2025.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 September 2025.	1 September 2025
2. Schedule 1	1 September 2025.	1 September 2025
3. Schedule 2	1 October 2025.	1 October 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 September 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:				
Aciclovir	Tablet 800 mg	Oral	Aciclovir APOTEX	4 months stock by reference to usual demand of both Aciclovir APOTEX and ARX-ACICLOVIR added together

2 Schedule 1 (table)

Omit:				
Amisulpride	Tablet 400 mg	Oral	Amipride 400	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

3 Schedule 1 (table)

Omit:				
Celecoxib	Capsule 100 mg	Oral	Blooms the Chemist Celecoxib	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

4 Schedule 1 (table)

Omit:				
Fentanyl	Transdermal patch 1.28 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
Fentanyl	Transdermal patch 10.20 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
Fentanyl	Transdermal patch 12.375 mg	Transdermal	Fenpatch 75	between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand

5 Schedule 1 (table)

Omit:

Fentanyl	Transdermal patch 2.063 mg	Transdermal	Fenpatch 12	between 1 August 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	-------------------------------	-------------	-------------	--

6 Schedule 1 (table)

Omit:

Fentanyl	Transdermal patch 2.55 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	------------------------------	-------------	--------	--

7 Schedule 1 (table)

Omit:

Fentanyl	Transdermal patch 5.10 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	------------------------------	-------------	--------	--

Fentanyl	Transdermal patch 7.65 mg	Transdermal	Denpax	between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand
----------	------------------------------	-------------	--------	--

8 Schedule 1 (table)

Omit:

Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection	Hymenoptera Yellow Jacket Venom	6 months stock by reference to usual PBS demand
---	--	-----------	---------------------------------	---

substitute:

Insect allergen extract-yellow jacket venom	Injection set containing 550 micrograms	Injection	Albey Yellow Jacket Venom	6 months stock by reference to usual PBS demand of Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms with diluent, Injection (Hymenoptera Yellow Jacket Venom) and Insect allergen extract-yellow jacket venom, Injection set containing 550 micrograms, Injection (Albey Yellow Jacket Venom)
---	---	-----------	---------------------------	---

9 Schedule 1 (table)

Omit:

Irbesartan with hydrochlorothiazide	Tablet 150 mg-12.5 mg	Oral	Blooms the Chemist Irbesartan HCTZ 150/12.5	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand
Irbesartan with hydrochlorothiazide	Tablet 300 mg-12.5 mg	Oral	Blooms the Chemist Irbesartan HCTZ 300/12.5	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

10 Schedule 1 (table)

After:				
Modafinil	Tablet 100 mg	Oral	Modafinil Viatris	after 28 February 2025—4 months stock by reference to usual demand of both Modafinil Viatris and Modafinil Mylan added together
insert:				
Mometasone	Ointment containing mometasone furoate 1 mg per g, 15 g	Application	Momasone	between 1 September 2025 to 28 February 2026—0 months stock by reference to usual demand

11 Schedule 1 (table)

Omit:				
Olanzapine	Tablet 10 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 10 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 10 mg (orally disintegrating), Oral, added together

12 Schedule 1 (table)

Omit:				
Olanzapine	Tablet 15 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 15 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 15 mg (orally disintegrating), Oral, added together.

13 Schedule 1 (table)

Omit:				
Olanzapine	Tablet 20 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral;
				(b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 20 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 20 mg (orally disintegrating), Oral, added together

14 Schedule 1 (table)

Omit:				
Olanzapine	Tablet 5 mg (orally disintegrating)	Oral	Zypine ODT	(a) between 1 February 2024 and 30 September 2024—4 months stock by reference to usual demand of the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral; (b) between 1 October 2024 and 31 March 2025—4 months stock by reference to usual demand of both the brand Zypine ODT of the pharmaceutical item Olanzapine, Wafer 5 mg, Oral and the brand Zypine ODT of the pharmaceutical item Olanzapine, Tablet 5 mg (orally disintegrating), Oral, added together

15 Schedule 1 (table)

Omit:				
Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir APOTEX	4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together

16 Schedule 1 (table)

Omit:				
Vinorelbine	Solution for I.V. infusion 50 mg (as tartrate) in 5 mL	Injection	Navelbine	between 1 July 2025 to 31 August 2025—0 months stock by reference to usual demand

Schedule 2—Amendments commencing 1 October 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Budesonide	Omit:	Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	6 months stock by reference to usual PBS demand
	substitute:				
Budesonide		Nebuliser suspension 500 micrograms in 2 mL single dose units, 30	Inhalation	Pulmicort Respules	(a) between 1 October 2025 and 31 March 2026— 7,770 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand

2 Schedule 1 (table)

Budesonide	Omit:	Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by Mouth	Pulmicort Turbuhaler	6 months stock by reference to usual PBS demand
	substitute:				
Budesonide		Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses	Inhalation by Mouth	Pulmicort Turbuhaler	(a) between 1 October 2025 and 31 March 2026— 31,080 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand

3 Schedule 1 (table)

Omit:				
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	4 months stock by reference to usual PBS demand
substitute:				
Ondansetron	Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL	Oral	Zofran syrup 50 mL	(a) between 1 October 2025 and 31 March 2026—2,204 packs of a pack quantity of 1 (b) after 31 March 2026—4 months stock by reference to usual PBS demand

4 Schedule 1 (table)

Omit:				
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	6 months stock by reference to usual PBS demand
substitute:				
Permethrin	Cream 50 mg per g, 30 g	Application	Lyclear	(a) between 1 October 2025 and 31 March 2026—25,734 packs of a pack quantity of 1 (b) after 31 March 2026—6 months stock by reference to usual PBS demand